Innovative Analytical Strategies To Address Common Development Challenges Of New Molecular Formats

Today's biopharmaceutical landscape is seeing a rise in complex next-generation biological molecules. These molecules, with their intricate structures and variations compared to traditional antibody formats, present unique challenges for manufacturers.

This webinar leverages case studies to explore innovative analytical strategies that tackle common hurdles faced during the development of these new molecular formats. Challenges like chain assembly, molecules with multiple mechanisms of action (MoAs), and the presence of diverse post-translational modifications are addressed. Additionally, the webinar focuses on meeting Biologics License Application (BLA) requirements and ensuring thorough process characterization.

Speaker:

Ian Anderson, Global Senior Principal Scientist – Global Analytical Development, Lonza

Ian earned both his BSc (Biochemistry) and PhD (Breast cancer cell signaling) at the University of Liverpool, followed by post doctoral research at University College London focused on HIV research using model lentiviral vectors. He has over 10 years industrial experience working for Allergan, AbbVie and Pharmaron gene therapy, focusing on analytical control strategies for numerous complex recombinant proteins, NME and AAV from pre-clinical through to commercial stages.